TY - JOUR
T1 - Factors associated with the intention to participate in COVID-19 vaccine clinical trials
T2 - A cross-sectional study in Peru
AU - De-Los-Rios-Pinto, Abraham
AU - Fernandez-Guzman, Daniel
AU - Soriano-Moreno, David R.
AU - Sangster-Carrasco, Lucero
AU - Morocho-Alburqueque, Noelia
AU - Pinedo-Soria, Antony
AU - Murrieta-Ruiz, Valentina
AU - Diaz-Corrales, Angelica
AU - Alave, Jorge
AU - Nieto-Gutierrez, Wendy
AU - Gonzales-Zamora, Jose
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/6/9
Y1 - 2022/6/9
N2 - Objective: To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods: Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. Results: Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15–1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09–1.28) or jungle (RPa: 1.30; 95% CI: 1.15–1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06–1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17–1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29–1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). Conclusion: There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.
AB - Objective: To evaluate the factors associated with the intention to participate in COVID-19 vaccine clinical trials in the Peruvian population. Methods: Cross-sectional study and secondary analysis of a database that involved Peruvian population during September 2020. The Poisson regression model was used to estimate the associated factors. Results: Data from 3231 individuals were analyzed, 44.1% of whom intended to participate in COVID-19 vaccine clinical trials. Factors associated with the outcome were being male (RPa: 1.25; 95% CI: 1.15–1.35), being from the highlands region (RPa: 1.18; 95% CI: 1.09–1.28) or jungle (RPa: 1.30; 95% CI: 1.15–1.47), having a relative that is a healthcare professional (PRa: 1.16; 95% CI: 1.06–1.28), using a medical source of information (PRa: 1.28; 95% CI: 1.17–1.41), and trusting in the possible effectiveness of vaccines (PRa: 1.40; 95% CI: 1.29–1.51). The main reason for not participating in the trial was the possibility of developing side effects (69.80%). Conclusion: There is an urgent need to generate a perception of safety in COVID-19 vaccine clinical trials, to increase the population's intention to participate in these studies, and to provide evidence-based information about the vaccine.
KW - Associated factors
KW - COVID-19
KW - Clinical Trial
KW - Coronavirus
KW - Intention to participate
KW - Vaccine
UR - http://www.scopus.com/inward/record.url?scp=85130398533&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2022.04.003
DO - 10.1016/j.vaccine.2022.04.003
M3 - Artículo
C2 - 35589452
AN - SCOPUS:85130398533
SN - 0264-410X
VL - 40
SP - 3566
EP - 3572
JO - Vaccine
JF - Vaccine
IS - 26
ER -
